Tags : Hikma

Sun Pharma Signs a License Agreement with Hikma for Ilumya

Shots: SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya.  Hikma will be responsible for the registration and commercialization of the product in all MENA markets Hikma’s presence in the MENA region will enable access to a new treatment option for people who are unable to manage their […]Read More

PharmaShots Weekly Snapshot (February 24-28, 2020)

1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, US, FDA, Approval, Fixed Dosing, Meal Estimation 2.  Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active […]Read More

Hikma Signs an Exclusive License Agreement with Glenmark to Commercialize

Shots: Glenmark to receive up front, regulatory & commercial milestones along with royalties on sales of Ryaltris in the licensed territory. Glenmark will continue the development of the therapy and is responsible for the US FDA approval Following the approval, Hikma will commercialize the therapy in the US. The focus of the collaboration is to […]Read More